Clinical Trial: NCT03873805
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | City of Hope Medical Center |
| Information Provided By: | City of Hope Medical Center |
| Last Update Posted: | 2026-06-02 |
Study Overview
Brief Summary
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to other places in the body (metastatic). PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells. This is done by using a virus to insert a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize prostate tumor cells. It is not yet known how well PSCA-CAR T cells works in killing tumor cells in patients with metastatic castration resistant prostate cancer.
Official Title
Conditions
Intervention / Treatment
- Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Fludarabine Phosphate
Other Study ID Numbers
- 17483
- NCI-2019-01264
- 17483
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | City of Hope Medical Center |
| Information Provided By: | City of Hope Medical Center |
| Last Update Posted: | 2026-06-02 |
Study Overview
Brief Summary
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to other places in the body (metastatic). PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells. This is done by using a virus to insert a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize prostate tumor cells. It is not yet known how well PSCA-CAR T cells works in killing tumor cells in patients with metastatic castration resistant prostate cancer.
Official Title
Conditions
Intervention / Treatment
- Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Fludarabine Phosphate
Other Study ID Numbers
- 17483
- NCI-2019-01264
- 17483